"MN-305"@en . . . . . . . . . . . . "# Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S166-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10609697"@en . . . . . "MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)."@en . . . . . . . . "investigational"@en . . . . . "Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders."@en . . "MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects."@en .